Skip to main content

FTC Asks Varian, Agilent for More Information

NEW YORK (GenomeWeb News) – The US Federal Trade Commission has asked Varian and Agilent Technologies for additional information in connection with Agilent's proposed $1.5 billion acquisition of Varian.

Palo Alto, Calif.-based Varian said in a filing with the US Securities and Exchange Commission this week that the FTC asked both firms for more information, but it did not provide further details. The company said that the request "extends the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after Agilent and Varian have substantially complied with the second request unless that period is extended voluntarily by the parties or terminated sooner by the FTC."

Agilent and Varian inked the merger agreement in late July. The firms said at the time that they expect to close the deal by the end of 2009.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.